Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report) shot up 34.9% on Wednesday . The company traded as high as $0.60 and last traded at $0.56. 16,694 shares traded hands during trading, an increase of 26% from the average session volume of 13,224 shares. The stock had previously closed at $0.42.
Defence Therapeutics Stock Performance
The stock has a 50-day simple moving average of $0.40 and a two-hundred day simple moving average of $0.46.
Defence Therapeutics Company Profile
Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.
Further Reading
- Five stocks we like better than Defence Therapeutics
- What is the Dow Jones Industrial Average (DJIA)?
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- Insider Trades May Not Tell You What You Think
- 3 Buy-and-Hold Stocks for Long-Term Growth
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
